Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Shares Outstanding (Weighted Average) (2020 - 2026)

Mereo BioPharma has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $801.8 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.23% to $801.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $801.8 million through Mar 2026, up 2.23% year-over-year, with the annual reading at $797.1 million for FY2025, 7.77% up from the prior year.
  • Shares Outstanding (Weighted Average) was $801.8 million for Q1 2026 at Mereo BioPharma, up from $797.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $2.2 billion in Q2 2022 and troughed at $623.9 million in Q1 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $770.1 million (2024), against an average of $846.3 million.
  • Year-over-year, Shares Outstanding (Weighted Average) surged 29806.1% in 2022 and then dropped 6.79% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $707.5 million in 2022, then decreased by 6.79% to $659.5 million in 2023, then grew by 12.16% to $739.6 million in 2024, then grew by 7.77% to $797.1 million in 2025, then grew by 0.59% to $801.8 million in 2026.
  • Per Business Quant, the three most recent readings for MREO's Shares Outstanding (Weighted Average) are $801.8 million (Q1 2026), $797.1 million (Q4 2025), and $799.9 million (Q3 2025).